Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α

References

• Sattar N, McCarey DW, Capell H, et al. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2963.
   PubMed Web of Science ®Google Scholar
• Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106:640–642.
   PubMed Web of Science ®Google Scholar
• Maruotti N, d’Onofrio F, Cantatore FP. Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med. 2015;15:433–438.
   PubMed Web of Science ®Google Scholar
• da Cunha VR, Brenol CV, Brenol JC, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012;41:186–191.
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196:756–763.
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–949.
   PubMed Web of Science ®Google Scholar
• Kang Y, Park HJ, Kang MI, et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15:R194.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J ClinEndocrinolMetab. 2000;85:2402–2410.
   PubMed Web of Science ®Google Scholar
• Del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–2745.
   PubMed Web of Science ®Google Scholar
• Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, et al. Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome. Atherosclerosis. 2018;271:84–91.
   PubMed Web of Science ®Google Scholar
• Medina G, Vera-Lastra O, Peralta-Amaro AL, et al. Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res. 2018;133:277–288.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482–487.
   PubMed Web of Science ®Google Scholar
• Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9:513–523.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis. 2014;73:1281–1283.
   PubMed Web of Science ®Google Scholar
• McGrath CM, Young SP. Lipid and metabolic changes in rheumatoid arthritis. Curr Rheumatol Rep. 2015;17:57.
   PubMed Web of Science ®Google Scholar
• Boers M, Nurmohamed MT, Doelman CJA, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842–845.
   PubMed Web of Science ®Google Scholar
• BatúnGarrido JA, Olán F, Hernández Núñez É. Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis. Clin Investig Arterioscler. 2016;28:123–131.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Carrio J, Alperi-López M, López P, et al. High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: a potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. J Clin Lipidol. 2017;11:1043–1054.
   PubMed Web of Science ®Google Scholar
• Tejera-Segura B, Macía-Díaz M, Machado JD, et al. HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther. 2017;19:113.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee EY, Park JK, et al. Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS One. 2016;11:e0164564.
   PubMed Web of Science ®Google Scholar
• Francisco V, Pino J, Gonzalez-Gay MA, et al. Adipokines and inflammation: is it a question of weight? Br J Pharmacol. 2018;175:1569–1579.
   PubMed Web of Science ®Google Scholar
• Kwon H, Kim D, Kim JS. Body fat distribution and the risk of incident metabolic syndrome: a Longitudinal Cohort Study. Sci Rep. 2017;7:10955.
   PubMed Web of Science ®Google Scholar
• Kerekes G, Nurmohamed MT, González-Gay MA, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10:691–696.
   PubMed Web of Science ®Google Scholar
• Ferraz-Amaro I, González-Juanatey C, López-Mejias R, et al. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013;2013:710928.
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765–766.
   PubMed Web of Science ®Google Scholar
• Parveen S, Jacob R, Rajasekhar L, et al. Serum lipid alterations in early rheumatoid arthritis patients on disease modifying anti-rheumatoid therapy. Indian J Clin Biochem. 2017;32:26–32.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46:71–80.
   PubMed Web of Science ®Google Scholar
• Naerr GW, Rein P, Saely CH, et al. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol. 2016;81:22–30.
   PubMed Web of Science ®Google Scholar
• Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci. 2009;116:219–230.
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou AD, Kitas GD, et al. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19:pii: E1890.
   Web of Science ®Google Scholar
• Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. MediatorsInflamm. 2012;2012:674265.
   Google Scholar
• Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998;182:169–175.
   PubMed Web of Science ®Google Scholar
• Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11:212–217.
   PubMed Web of Science ®Google Scholar
• Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10:19–29.
   PubMed Web of Science ®Google Scholar
• McDevitt H, Munson S, Ettinger R, et al. Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity. Arthritis Res. 2002;4:S141–S152.
   PubMedGoogle Scholar
• Hassan S, Milman U, Feld J, et al. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther. 2016;18:261.
   PubMed Web of Science ®Google Scholar
• Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alphatreatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:414–419.
   PubMed Web of Science ®Google Scholar
• Daïen CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71:862–868.
   PubMed Web of Science ®Google Scholar
• Souto A, Salgado E, Maneiro JR, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015;67:117.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves binsulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83–86.
   PubMed Web of Science ®Google Scholar
• Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenousanti-TNF-alpha antibody therapy leads to elevated triglyceride and reducedHDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien KlinWochenschr. 2002;114:1004–1007.
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1316.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905–2912.
   PubMed Web of Science ®Google Scholar
• Branen L, Hovgaard L, Nitulescu M, et al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137–2142.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:596–603.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:311–316.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:222–228.
   PubMed Web of Science ®Google Scholar
• Toussirot É, Mourot L, Dehecq B, et al. CBT-506. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr. 2014;53:951–961.
   PubMed Web of Science ®Google Scholar
• Abella V, Scotece M, Conde J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014;2014:1.
   Web of Science ®Google Scholar
• Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:1.
   Web of Science ®Google Scholar
• Foucan L, Maimaitiming S, Larifla L, et al. Adiponectin gene variants, adiponectin isoforms and cardiometabolic risk in type 2 diabetic patients. J Diabetes Investig. 2014;5:192–198.
   PubMed Web of Science ®Google Scholar
• Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res. 2007;56:459–467.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence ofanti-TNF-alpha infliximab therapy on adhesion molecules associated with athero genesis in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:373–379.
   PubMed Web of Science ®Google Scholar
• Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495–1498.
   PubMed Web of Science ®Google Scholar